105 abstracts, judged to be of the highest standard, were selected for platform presentation in 18 sessions throughout the programme.

Adult epileptology

Co-chairs: Jera Kruja (Albania) & Dana Ekstein (Israel)

  • Cerebrospinal fluid profile in epilepsy considering exclusion of an autoimmune origin – Marie Süße (Germany)
  • Automated free-water imaging analysis in patients with epilepsy and focal cortical dysplasia – Barbara Anne Katharina Kreilkamp (United Kingdom)
  • Disrupted basal ganglia networks in GLUT1 Deficiency Syndrome: different connectivity pattern at different stages of life – Anna Elisabetta Vaudano (Italy)
  • Neuronal antibodies in a prospective, multicenter cohort of patients with focal epilepsy of unknown origin – Marienke de Bruijn (Netherlands)
  • Outcomes among adult patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures treated with adjunctive everolimus: Final analysis of the EXIST-3 study – Adelheid Wiemer-Kruel (Germany)
  • Risk of stroke after late-onset seizures: a Swedish register-based case-control study – David Larsson (Sweden)

Basic science 1

Co-chairs: Jose Serratosa (Spain) & Aljoscha Thomschewski (Austria)

  • The anti-epileptic effect of spinal cord stimulation in kainic acid induced epilepsy rat model – Akihiko Kondo (Japan)
  • Pathological connectivity of the hippocampal CA2 region in temporal lobe epilepsy – Ute Häussler (Germany)
  • Dynamic interaction of local and transhemispheric networks is necessary for progressive intensification of hippocampal seizures – Fredrik Berglind (Sweden)
  • Novel approaches to detect post-ictal cortical spreading depression (CSD) in awake rodents – Robert Wykes (United Kingdom)
  • Altered GABAergic transmission underlies epileptogenicity in human pediatric Focal Cortical Dysplasia – Thomas Blauwblomme (France)
  • To study the effect of Embelin on neurogenesis and cognition in PTZ induced epilepsy model of adult zebrafish  – Uday Kundap (Malaysia)

Basic science 2

Co-chairs: Davor Sporiš (Croatia) & Günther Sperk (Austria)

  • Suppression of spike-and-wave discharges by an alpha 2 adrenergic receptor blocker, atipamezole, in a genetic absence epilepsy rat model – Melis Yavuz (Turkey)
  • A combination of levetiracetam and topiramate exerts disease-modifying effects in the intrahippocampal kainate mouse model – Alina Schidlitzki (Germany)
  • Chemogenetic silencing of excitatory hippocampal neurons prevents spontaneous seizures in a mouse model for temporal lobe epilepsy – Jana Desloovere (Belgium)
  • The effect of chemogenetic inhibition of excitatory neurons on hippocampal excitability and seizure frequency in a rat model – Marie-Gabrielle Goossens (Belgium)
  • Biochemical autoregulatory gene therapy for intractable focal epilepsy – Andreas Lieb (United Kingdom)
  • State-dependent effect of interictal epileptiform discharges – Jan Chvojka (Czech Republic)


Basic science 3

Co-chairs: Cecilie Johannessen Landmark (Norway) & Piero Perucca (Australia)

  • Epilepsy, β amyloid and D1 dopamine receptors: a possible pathogenetic link? – Cinzia Costa (Italy)
  • Antiepileptic properties of combinatorial NPY and Y2 receptor gene therapy in a chronic model of temporal lobe epilepsy – Esbjörn Melin (Sweden)
  • Effects of common antiepileptic drugs on biomarkers of oxidative stress in a human neuroblastoma cell line – Reyadh Al-Mosawi (United Kingdom)
  • Alpha-lactalbumin protects against pentylenetetrazole-induced seizures in mice reducing intestinal inflammation – Emilio Russo (Italy)
  • Valproate, carbamazepine and levetiracetam cause bone loss and modulate Wntinhibitors: A comparative evaluation in normal and ovariectomised rats – Divya Vohora (India)
  • Systemic delivery of antagomirs targeting miR-134 timed with blood-brain barrier opening are disease-modifying in experimental epilepsy – Cristina Reschke (Ireland)

Clinical epileptology

Co-chairs: Elinor Ben-Menachem (Sweden) & Silvio Basic (Croatia)

  • Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide – David Bibi (Israel)
  • Increased network segregation as a biomarker in focal epilepsy – Margherita Carboni (Switzerland)
  • Costs derived from of Status epilepticus (EE): associated factors and relationship with duration – Estevo Santamarina (Spain)
  • Functional mapping of emotion recognition in epilepsy patients: an intracranial EEG study – Adam Kalina (Czech Republic)
  • Siblings of Epileptic Encephalopathy Patients Are at Risk for Depression and Anxiety: Results from the Sibling Voices Survey – Laurie Bailey (USA)
  • Sexual dysfunction in patients with epilepsy – Stjepan Jurić (Croatia)

Clinical neurophysiology

Co-chairs: Firas Fahoum (Israel) & Reetta Kälviäinen (Finland)

  • Post-ictal EEG suppression: an SEEG study of 100 generalized tonic-clonic seizures – Aileen McGonigal (France)
  • Distinct interictal HFO coupling with different seizure onset patterns – Mina Amiri (Canada)
  • Physiological ripples (80-250 Hz) are common in eloquent cortical areas: region-specific normative values – Birgit Frauscher (Austria/Canada)
  • Single-neuron activity preceding human epileptic seizures – Firas Fahoum (Israel)
  • Clinical utility of high versus low-density EEG source imaging in presurgical evaluation: impact on decision making – Mette Thrane Foged (Denmark)
  • Multi-day Periodicity in Epilepsy – Maxime Baud (Switzerland)


Clinical pharmacology

Co-chairs: Sara Eyal (Israel) & Martin Brodie (United Kingdom)

  • Maintained safety and efficacy of cannabidiol in a long-term open-label trial in patients with Lennox-Gastaut syndrome (GWPCARE5) – M Mazurkiewicz-Bełdzińska (Poland)
  • Effect of anti-epileptic drugs on biomarkers of excitotoxic brain damage in focal seizures: A randomized controlled trial – Rituparna Maiti (India)
  • GENERAL study: 1-year real-life effectiveness and tolerability of perampanel in idiopathic generalized epilepsy – Vicente Villanueva (Spain)
  • Comparison of human brain penetration and target/SV2A affinities of brivaracetam and levetiracetam by PET – Rafal Kaminski (Belgium)
  • Bidirectional drug-drug interaction with coadministration of cannabidiol and clobazam in a Phase 1 healthy volunteer trial – Volker Knappertz (USA)
  • Exposure-response analysis of cannabidiol for the treatment of Lennox-Gastaut syndrome – Gilmour Morrison (United Kingdom)


Co-chairs: Mahmoud Motamedi (Iran) & Joanna Jedrzejczak (Poland)

  • Secular trends in sudden unexpected death in epilepsy (SUDEP) and other epilepsy-related deaths in adults: a nationwide population-based study – Gashirai Mbizvo (United Kingdom)
  • Car crash semiology: characteristics of motor vehicle crashes associated with seizure – Andrew Neal (Australia)
  • Epilepsy, mortality and population risk factors in the province of Saskatchewan, Canada (2005-2010) – Lizbeth Hernandez Ronquillo (Canada)
  • Quality of Life in Individuals with Epilepsy – Marie Normark Holmgaard (Denmark)
  • Sex differences in febrile seizures – Jakob Christensen (Denmark)
  • Cost savings and improved patient outcomes from best management of epilepsy – Tony Marson (United Kingdom)

Epilepsy and women; Neurostimulation

Co-chairs: Torbjörn Tomson (Sweden) & Ruta Mameniskiene (Lithuania)

  • The influence of Anti-Epileptic Drug modifications in second or third trimester of pregnancy on fetal outcome – Ajay Asranna (India)
  • Ex vivo effects of valproic acid on the human placental barrier: Findings from gene array studies – Nino Tetro (Israel)
  • Behavioral effects after in uteroexposure to antiepileptic drugs and associations with family factors: preliminary results of the Dutch observational study EURAP & Development (NL)  – Yfke Huber-Mollema (Netherlands)
  • Electrical stimulation for seizures induction during SEEG exploration: are they useful or not? – Renata Racila (France)
  • TMS-EEG as a tool to study the neuromodulatory effects of theta burst stimulation – Sofie Carrette (Belgium)
  • Epileptiform activity detected within the anterior nucleus of the thalamus in temporal lobe epilepsy patients – Daniel Fabo (Hungary)


Epilepsy in childhood 1

Co-chairs: Nana Tatishvili (Gerogia) & Federico Vigevano (Italy)

  • Prospective video EEG tracking of infants with Tuberous Sclerosis Complex (TSC) in the first year of life – Jessie De Ridder (Belgium)
  • Dravet Syndrome, PCDH19-related epilepsy and SCN1A-related epilepsies: early differential diagnosis – Serena Pellegrin (Italy)
  • Seizure frequency, overall healthcare resource utilization, and all-cause mortality in children with epilepsy in the UK – Richard Chin (United Kingdom)
  • Cannabidiol treatment effect and adverse events in patients with Lennox-Gastaut syndrome: pooled results from two trials – Antonio Gil-Nagel (Spain)
  • Long-term efficacy and safety of everolimus among pediatric patients with tuberous sclerosis complex (TSC) and treatment-refractory seizures: Final analysis of the EXIST-3 study – Christoph Hertzberg (Germany)
  • Long-term efficacy and safety of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures: Final analysis of the EXIST-3 study – Tilman Polster (Germany)

Epilepsy in childhood 2

Co-chairs: Nicola Specchio (Italy) & Sofia Kasradze (Georgia)

  • Prevalence and prognostic risk factors of refractory juvenile myoclonic epilepsy: A systematic review and meta-analysis – Remi Stevelink (Netherlands)
  • Perampanel (PER) add-on therapy in children with refractory focal epilepsy: are there any most efficacious AED combinations? – Marina Nikanorova (Denmark)
  • The association of polymorphisms in genes involved in metabolism and transport of antiepileptic drugs with the presence of adverse drug reactions in Slovenian children and adolescents with epilepsy – Zvonka Rener Primec (Slovenia)
  • Prenatal MRI and correlation with outcome at two years in children with Tuberous Sclerosis Complex – HM Hulshof (Netherlands)
  • Health-related quality of life in a European study of non-institutionalized children with epilepsy – Lieven Lagae (Belgium)
  • Impaired sleep in infants with early-onset epilepsy: comparison to typically developing peers and predictors – Manuela Pisch (United Kingdom)

Epilepsy surgery & neuroimaging

Co-chairs: Silvia Bonelli (Austria) & Emilija Cvetkovska (FYR Macedonia)

  • Motor Network Hypersynchrony as an Endophenotype in Families with Genetic Generalised Epilepsy: a resting state fMRI study – Mark Richardson (United Kingdom)
  • Subcortical diffusional kurtosis imaging and antiepileptic drug treatment outcome in newly diagnosed focal epilepsy – Lorna Bryant (United Kingdom)
  • Functional connectivity of left temporal lobe language networks in temporal lobe epilepsy – Karin Trimmel (United Kingdom)
  • In-vivo imaging evidence for a human area tempestas: a crucial site influencing outcome after epilepsy surgery – Marian Galovic (United Kingdom)
  • When to stop antiepileptic drugs after pediatric epilepsy surgery? Presentation of a new prediction tool – Herm Lamberink (United Kingdom)
  • Lateral vs parasagittal hemispherotomy: technical note, outcome and their predictors in a multicenter Italian cohort – Luca De Palma (Italy)


Epilepsy surgery 1

Co-chairs: Andriy Dubenko (Ukraine) & Mar Carreño (Spain)

  • Seizure Outcomes after resective single-stage Epilepsy Surgery in Children and Adolescents – Gudrun Gröppel (Austria)
  • Comparison of subdural grid electrodes and SEEG in patients with refractory epilepsy in four large European centers – Matea Rados (Netherlands)
  • Individual prediction of post-operative verbal memory decline in temporal lobe epilepsy: the contribution of postictal memory testing – Lukas Sveikata (Switzerland)
  • Trans-third ventricular approach of stereotactic radiofrequency thermocoagulation for hypothalamic hamartoma with bilateral hypothalamic attachment – Hiroshi Shirozu (Japan)
  • Multi-unit activity underlies epileptic fast ripple EEG in the mesial temporal lobe – Fedele Tommaso (Switzerland)
  • Seizure control after hemispherotomy in childhood and adolescence: can we predict outcomes? – Georgia Ramantani (Switzerland)

Epilepsy surgery 2

Co-chairs: John Duncan (United Kingdom) & Ekaterina Pataraia (Austria)

  • The immediate and short-term effects of bilateral intrahippocampal depth electrodes on verbal memory – Christoph Helmstaedter (Germany)
  • Negative motor areas investigated with intracranial depth electrodes – Leyla Baysal-Kirac (Germany)
  • Endoscopic Assisted Hemispherotomy: A Comparative Study With Open Hemispherotomy To Evaluate Efficacy, Complications And Outcome – Sarat Chandra (India)

Epileptic encephalopathies

Co-chairs: Nebojsa Jović (Serbia) & Gerhard Kluger (Germany)

  • SYNGAP1 developmental and epileptic encephalopathy: delineating the phenotypic spectrum – Danique Rienke Maria Vlaskamp (Australia)
  • Adult-onset Rasmussen encephalitis: rational long-term management of relapses and disease progression – Andrea Stabile (Italy)
  • The socio-economic impact of Dravet syndrome on patients and their caregivers in Germany – Adam Strzelczyk (Germany)
  • Effects on brain excitability of human healthy IgGs – Laura Librizzi (Italy)
  • Risk factors for early mortality in SCN8Arelated epilepsy  – Elena Gardella (Denmark)
  • Late-onset anti-N-methyl-D-aspartate receptor encephalitis in China – Le Zhang (China)

Late-breaking abstracts

Co-chairs: Tim von Oertzen (Austria) & Milan Brázdil (Czech Republic)

  • A Phase 2 Trial to Explore the Potential for a Pharmacokinetic Drug-drug Interaction with Valproate when in Combination with Cannabidiol in Adult Epilepsy Patients – Elinor Ben-Menachem (Sweden)
  • A first-in-human phase I study to assess the pharmacodynamic profile of a novel potassium channel opener (XEN1101) on human cortical excitability with TMS-EEG and TMS-EMG – Isabella Premoli (United Kingdom)
  • Automated EEG source imaging: a retrospective, blinded clinical validation study – Amir G. Baroumand (Belgium)
  • Generalized polyspike train: an EEG biomarker of drug-resistant idiopathic generalized epilepsy – Yanping Sun (China)
  • Microstructural imaging in mesial temporal lobe epilepsy: role of neurite density and myelination – Gavin Paul Winston (United Kingdom)
  • Volumetry of hippocampal subfields in patients with antibody-associated limbic encephalitis – Theodor Rüber (Germany)

Psychiatry & neuropsychology

Co-chairs: Amos Korczyn (Israel) & Almasa Kapidzic (Bosnia & Herzegovina)

  • Cognitive features and surgical outcome of patients with long-term epilepsy associated tumors (LEAT) within the temporal lobe – Viola Vogt (Germany)
  • Suicide risk in antiepileptic drug users – the role of previous suicidal behavior and psychiatric disease – Julie Werenberg Dreier (Denmark)
  • Frequency and severity of challenging behaviour among adults with epilepsy and intellectual disability – Jans van Ool (Netherlands)
  • Assessment of ADHD in a cohort of children and adolescents with epilepsy – Francesca Cervi (Italy)
  • Parent’s anxiety and coping with their child’s new-onset epilepsy: association with children’s internalizing and externalizing behaviour – Daša Kocjančič (Slovenia)
  • Early neurodevelopmental profiles and family impact in newly diagnosed epilepsy: Findings from a 3-year prospective cohort – Liam Dorris (United Kingdom)

Status Epilepticus

Co-chairs: Jafar Mehvari Habibabadi (Iran) & Markus Leitinger (Austria)

  • The essence of the first 2.5 hours in the treatment of generalized convulsive status epilepticus – Leena Kämppi (Finland)
  • Results from the Global Audit of Refractory Status Epilepticus – Monica Ferlisi (Italy)
  • Status epilepticus after experimental traumatic brain injury – Ivette Banuelos Cabrera (Finland)
  • Causes of Death in Status Epilepticus – Maximiliano Hawkes (USA)
  • Focal myoclonic status epilepticus in tick-borne Russian spring-summer encephalitis – Nadezhda Kvaskova (Russia)
  • Long-Term Mortality of Status Epilepticus in Thailand – Somsak Tiamkao (Thailand)


Please enter your comment!
Please enter your name here